Scottish biotech Cyclacel joins IPO bandwagon
05 July, 2004 by Staff WritersScottish cancer specialist Cyclacel has announced plans to float on Nasdaq and the London Stock Exchange.
LEK's McIntyre joins BioTech Capital board
01 July, 2004 by Iain ScottDr Lisa McIntyre, the head of LEK Consulting's Asia-Pacific life sciences practice, has joined the board of Sydney-based pooled development fund BioTech Capital (ASX:BTC).
NSW, feds to fund Sydney medical research complex
30 June, 2004 by Renate KrelleSydney's Victor Chang Cardiac Research Institute will get new digs, the Garvan Institute will get its building back, and both will be sharing café and confocal microscopy facilities with researchers from over the road at St Vincent's Hospital, if a $46 million new laboratory building gets underway.
From grapes to grants: new ARC head outlines plans
30 June, 2004 by Susan WilliamsonProf Peter Høj, currently director of the Australian Wine Research Institute, has been appointed the new CEO of the Australian Research Council (ARC).
Mind your fingers as the IPO window closes
29 June, 2004 by Renate KrelleMarket analysts are wondering whether the windown for Australian biotech IPOs has slammed shut.
UNSW spin-out Acyte collaborates with Serono
22 June, 2004 by Renate KrelleAcyte Biotechnology, a spin-out from the University of New South Wales, is to team up with Swiss biopharmaceutical giant Serono to develop recombinant proteins using Acyte's mammalian cell expression technology.
How Myriad's GCAT got out of the bag
21 June, 2004 by Graeme O'NeillThe past two decades have produced a plethora of patents for DNA diagnostic tests to determine people's susceptibility to common, life-threatening disorders like cancer, cardiovascular disease, hypertension and neurodegenerative diseases like Alzheimer's disease and motor neuron disease.
What not to do: the top 10 patenting mistakes
21 June, 2004 by Renate KrelleYou've run your experiments, got your results, and you've been mentally spending -- or at least licensing -- the proceeds of your bulging IP portfolio. But that may have been the easy part, writes Renate Krelle. Before you go any further, here's a checklist of some of the most common patenting pitfalls.
The end of the pioneer trail
21 June, 2004 by Melissa TrudingerAustralia's first ever Cooperative Research Centre is winding up operations. Melissa Trudinger joined its stakeholders for a look back at its successes.
COVER STORY: Lab to order
21 June, 2004 by Susan WilliamsonImagine if you could map out your dream lab on the concrete floor -- and then stock it with whatever you wanted. Susan Williamson spoke with Ian Findlay and his team at Gribbles Molecular Science, who did just that.
Interview: ViaLactia CEO Colin South
18 June, 2004 by Graeme O'NeillEven after its R&D budget was cut this week by parent company Fonterra, ViaLactia still has one of the biggest research budgets in New Zealand's biotechnology industry. CEO Colin South discussed his company's research programs with Australian Biotechnology News during a tour sponsored by New Zealand Trade and Enterprise in March.
Nanotech pioneer amongst new federation fellows
17 June, 2004 by Susan WilliamsonTwenty-five scientists will receive a $235,000 salary each year for the next five years, plus several hundred thousand dollars each in on-costs support, under the federation fellowships announced today by the federal government.
CRO Novotech springboards into US
15 June, 2004 by Melissa TrudingerAustralian CRO Novotech is setting up operations in the US to take advantage of the clinical trials opportunities offered there.
Watson to quit Genesis' helm
15 June, 2004 by Graeme O'NeillOne of the most familiar faces and names in New Zealand's biotechnology industry, Genesis Research & Development Corp CEO Dr Jim Watson, is retiring -- but only as far as the research bench.
Peptech and Agenix call off merger
09 June, 2004 by Renate KrelleSydney-based Peptech (ASX:PTD) and Brisbane-based Agenix (ASX:AGX) have called off their merger, citing Peptech's inability to provide Agenix with details of possible royalties due from Johnson & Johnson subsidiary Centocor.
